Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.15 AUD | +3.45% | 0.00% | +3.45% |
02-27 | Star Combo Pharma Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
2023 | Star Combo Pharma Limited Reports Earnings Results for the Full Year Ended June 30, 2023 | CI |
Valuation
Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 65.69 | 60.14 | 54.25 | 34.37 | 20.86 | 14.86 |
Enterprise Value (EV) 1 | 56.88 | 55.57 | 33.26 | 20.35 | 14.59 | 9.564 |
P/E ratio | -27.6 x | -33.1 x | -100 x | -4.36 x | -30 x | -3.67 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 6.03 x | 2.79 x | 1.39 x | 1.27 x | 0.91 x | 0.6 x |
EV / Revenue | 5.22 x | 2.57 x | 0.85 x | 0.75 x | 0.64 x | 0.39 x |
EV / EBITDA | -48.6 x | -28.8 x | -26.6 x | -13.2 x | 15.1 x | 5.87 x |
EV / FCF | -264 x | -223 x | -7.11 x | -2.31 x | -2.72 x | -9.28 x |
FCF Yield | -0.38% | -0.45% | -14.1% | -43.3% | -36.7% | -10.8% |
Price to Book | 4.04 x | 3.01 x | 1.22 x | 0.95 x | 0.59 x | 0.45 x |
Nbr of stocks (in thousands) | 75,505 | 86,537 | 135,617 | 134,792 | 134,583 | 135,083 |
Reference price 2 | 0.8700 | 0.6950 | 0.4000 | 0.2550 | 0.1550 | 0.1100 |
Announcement Date | 18-08-31 | 19-08-28 | 20-08-25 | 21-08-24 | 22-08-23 | 23-08-29 |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 10.9 | 21.59 | 39.08 | 26.97 | 22.96 | 24.74 |
EBITDA 1 | -1.169 | -1.926 | -1.252 | -1.536 | 0.966 | 1.629 |
EBIT 1 | -1.441 | -2.255 | -1.712 | -1.981 | 0.5353 | 1.123 |
Operating Margin | -13.21% | -10.44% | -4.38% | -7.34% | 2.33% | 4.54% |
Earnings before Tax (EBT) 1 | -2.172 | -2.338 | -0.9064 | -7.463 | -1.082 | -3.455 |
Net income 1 | -1.973 | -1.727 | -0.3487 | -7.876 | -0.6963 | -4.003 |
Net margin | -18.1% | -8% | -0.89% | -29.2% | -3.03% | -16.18% |
EPS 2 | -0.0315 | -0.0210 | -0.003999 | -0.0584 | -0.005174 | -0.0300 |
Free Cash Flow 1 | -0.2157 | -0.2497 | -4.678 | -8.801 | -5.355 | -1.031 |
FCF margin | -1.98% | -1.16% | -11.97% | -32.64% | -23.32% | -4.17% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 18-08-31 | 19-08-28 | 20-08-25 | 21-08-24 | 22-08-23 | 23-08-29 |
Balance Sheet Analysis
Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 8.81 | 4.57 | 21 | 14 | 6.27 | 5.3 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -0.22 | -0.25 | -4.68 | -8.8 | -5.36 | -1.03 |
ROE (net income / shareholders' equity) | -14.8% | -9.44% | -1.08% | -19.5% | -1.95% | -11.7% |
ROA (Net income/ Total Assets) | -5.22% | -6.01% | -2.63% | -2.53% | 0.77% | 1.64% |
Assets 1 | 37.81 | 28.71 | 13.28 | 311.9 | -90.31 | -244.3 |
Book Value Per Share 2 | 0.2200 | 0.2300 | 0.3300 | 0.2700 | 0.2600 | 0.2400 |
Cash Flow per Share 2 | 0.1200 | 0.0500 | 0.2000 | 0.1300 | 0.0300 | 0.0200 |
Capex 1 | 0.2 | 0.68 | 2.72 | 7.26 | 7.29 | 2.73 |
Capex / Sales | 1.82% | 3.14% | 6.95% | 26.91% | 31.77% | 11.02% |
Announcement Date | 18-08-31 | 19-08-28 | 20-08-25 | 21-08-24 | 22-08-23 | 23-08-29 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+3.45% | 13.53M | |
-.--% | 843M | |
+6.30% | 743M | |
+32.12% | 477M | |
+36.24% | 262M | |
0.00% | 130M | |
+134.78% | 63.1M |
- Stock Market
- Equities
- S66 Stock
- Financials Star Combo Pharma Limited